A Healing Method Holds Promise as Antidote to 9/11 Toxicity

There are many who still suffer from the tragic events of 9/11. A natural herbal detox program developed by an Ayurvedic physican shows a promise of relief. The study abstract, below.

Ayurvedic herbal supplements as an antidote to 9/11 toxicity
Dahl JJ, Falk K.

Phoenix House Foundation, New York, New York, USA.

An in-treatment web-based survey was conducted in 2005 with 50 New York World Trade Center rescue and recovery workers, volunteers, and area residents and workers who were treated with Ayurvedic herbs for post-9/11 symptoms. The survey documented pretreatment efforts at symptom relief, post-treatment symptom impact, and the context for using the herbal intervention. Herbal treatment was administered and monitored by a private non-profit organization. The natural detoxification and immune-strengthening program consists of 4 herbal supplements developed by an Ayurvedic physician. A minimum 6-month basic program was recommended, but many participants continued to 1 year and longer. All 50 respondents reported high incidence of alleviation of previously intractable symptoms, chiefly respiratory symptoms, fatigue, and depression.

Altern Ther Health Med. 2008 Jan-Feb;14(1):24-8

Oregon Couple Charged in Daughter’s Faith-Healing Death

Saturday, March 29, 2008
OREGON CITY, Ore. – A grand jury indicted an Oregon City couple accused of failing to seek medical treatment for their gravely ill daughter who died this month.

Carl Worthington, 28, and Raylene Worthington, 25, surrendered late Friday to face charges of manslaughter and criminal mistreatment, said Detective Jim Strovink of the Clackamas County Sheriff’s Office.

They were held on $250,000 bail each and their first court appearance was scheduled for Monday afternoon.

The couple’s daughter, 15-month-old Ava, died at home March 2 from bacterial bronchial pneumonia and infection. A deputy state medical examiner said Ava’s medical problems were treatable with antibiotics.

The Worthingtons belong to Oregon City’s Followers of Christ Church. According to church tradition, when members become ill, fellow worshippers pray and anoint them with oil.

Dozens of children have been buried in the parish cemetery over the past 50 years, and a 1998 analysis by The Oregonian newspaper found that many of the deaths could have prevented with medical care.

The 1999 Oregon Legislature eliminated the state’s “spiritual-healing defense” in cases of second-degree manslaughter, first- and second-degree criminal mistreatment and nonpayment of child support. Legislators were prompted by the death of 11-year-old Oregon City boy whose diabetes was left untreated. His parents were members of the Followers of Christ Church.

for more info on the Followers of Christ Church click here

Weekly Reflection #5

“If there is no strength in body and mind, the Atman (the Self) cannot be realized. First you have to build the body by good nutritious food – then only will the mind be strong. The mind is but the subtle part of the body. You must retain great strength in your mind and words. “I am low, I am low” – repeating these ideas in the mind, man belittles and degrades himself” – Vivekananda

‘Space Junk’ Falls Right Back To Earth

Chances are this will not stop expansion of the space program. However, it does demonstrate the adage, that what goes up does come back down. Take a look at progress, here.

CANBERRA (Reuters) – A cattle farmer in Australia’s remote northern outback on Friday said he had found a giant ball of twisted metal, which he believes is space junk from a rocket used to launch communications satellites.

Farmer James Stirton found the odd-shaped ball last year on his 40,000 hectare property, about 800 kilometers (500 miles) west of the northern Queensland state capital of Brisbane.

But Stirton only started inquiring into what the ball of metal really was, and where it had come from, in the past week.

“I was riding out to check some cattle, and I came around the corner and there it was in a paddock,” Stirton told Reuters on Friday.

“I know a lot of about sheep and cattle but I don’t know much about satellites. But I would say it is a fuel cell off some stage of a rocket.”

He said the object was hollow, and covered in a carbon-fiber material. He has contacted some U.S.-based aerospace companies to try to find out what the object really is.

Sydney’s Powerhouse Museum said it was not uncommon for people to find spacejunk in remote areas of Australia.

In 1979, large parts of the Skylab space station fell to earth near a tiny outback town in Australia’s west. A local council sent NASA a ticket for littering and then the United States President Jimmy Carter rang a local motel to apologize.

(Reporting by James Grubel; Editing by David Fox)

FDA Probing Possible Link Between Asthma Drug and Suicide Risk

FDA is investigating a possible association between the use of Singulair and behavior/mood changes, suicidality (suicidal thinking and behavior) and suicide. Singulair is a medicine in the drug class known as leukotriene receptor antagonists. Singulair is used to treat asthma and the symptoms of allergic rhinitis (sneezing, stuffy nose, runny nose, itching of the nose) and to prevent exercise-induced asthma.

Over the past year, the maker of Singulair, Merck & Co, Inc., has updated the prescribing information and patient information for Singulair to include the following post-marketing adverse events: tremor (March 2007), depression (April 2007), suicidality (suicidal thinking and behavior) (October 2007), and anxiousness (February 2008).

In February 2008, FDA and Merck discussed how best to communicate these labeling changes to prescriber’s and patients. Merck plans to highlight the recent changes in the prescribing information in face-to-face interactions with prescriber’s and provide prescriber’s with patient information leaflets about Singulair. The Singulair website includes the most current prescribing information and patient information for Singulair (www.singulair.com).

FDA is working with Merck to further evaluate a possible link between the use of Singulair and behavior/mood changes, suicidality and suicide in response to inquiries received by FDA. FDA has requested that Merck evaluate Singulair study data for more information about suicidality and suicide. FDA is reviewing the postmarketing reports it has received of behavior/mood changes, suicidality and suicide in patients who took Singulair.

Due to the complexity of the analyses, FDA anticipates that it may take up to 9 months to complete the ongoing evaluations. As soon as this review is complete, FDA will communicate the conclusions and recommendations to the public.

Other leukotriene modifying medications include zafirlukast (Accolate), which is also a leukotriene receptor antagonist and zileuton (Zyflo and Zyflo CR), which is a leukotriene synthesis inhibitor. FDA is reviewing postmarketing reports it has received of behavior/mood changes, suicidality and suicide in patients who took Accolate, Zyflo, and Zyflo CR and will assess whether further investigation is warranted.

This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs.

The FDA urges both healthcare professionals and patients to report side effects from the use of Singulair, Accolate, Zyflo, and Zyflo CR to the FDA’s MedWatch Adverse Event Reporting program

Influenza Vaccine in Infants Younger Than 6 Months of Age

This study, see below, assesses the need for infants less than 6 months old to receive influenza vaccine. The study is funded, designed and carried out by a vaccine manufacturer. Bias could be construed in the entire study.

There is on going discussion of how allergic reactions continue to rise in the population. Overuse of antibiotics is seen as a contributing factor (mind you, they were once hailed as ‘wonder drugs’), could the indiscriminate use of vaccines also be a contributing factor? The entire human race has lived without the need of vaccines at birth and throughout life at least since recorded history. Young children used to get sick and there is evidence it made them healthier. Mumps, measles, chicken pox were for the most part lived through. The body developed immunity against the ailment and life went on. Now, it is seen as a constant source of fear and on going threat. Why?
Here is the ‘study’ why healthy infants need influenza vaccine:

Safety and Tolerability of Cold-Adapted Influenza Vaccine, Trivalent, in Infants Younger Than 6 Months of Age

Timo Vesikari, MDa, Aino Karvonen, MDa, Helen M. Smith, BScb, Andrew Dunning, PhDc, Ahmad Razmpour, PhDc, Melanie K. Saville, MB, BSb, William C. Gruber, MDc and Bruce D. Forrest, MDc a Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
b Wyeth Vaccines Research, Taplow, United Kingdom
c Wyeth Vaccines Research, Pearl River, New York

OBJECTIVE. Young children are at high risk for influenza-related complications. Vaccination of close household contacts is recommended to provide indirect protection to children <6 months of age. Studies have shown that live, cold-adapted influenza vaccine, trivalent, is efficacious in children. To assess the risks associated with inadvertent exposure of infants to vaccine viruses from vaccinated contacts, this study was designed to evaluate the safety and tolerability of cold-adapted influenza vaccine, trivalent, administered intranasally to healthy children 6 to <24 weeks of age.

METHODS. Healthy infants aged 6 to <16 weeks and 16 to <24 weeks, respectively, were randomly assigned to receive 2 doses of influenza vaccine, or placebo intranasally 35 ± 7 days apart. Reactogenicity events were monitored for 11 days after each dose. Other adverse events were monitored through 28 to 35 days after dose 2.

RESULTS. Of the infants aged 6 to <16 weeks, 31 received influenza vaccine and 28 received placebo, and of those aged 16 to <24 weeks, 30 received influenza vaccine and 31 received placebo. In the 6- to <16-week cohort, more influenza vaccine, recipients experienced irritability (66.7% vs 35.7%) and runny nose or nasal congestion (63.3% vs 33.3%) after dose 1 but not dose 2. There were no significant increases in any other reactogenicity events or adverse events in the vaccine recipients compared with the placebo group.

CONCLUSIONS. Although there was an increase in mild reactogenicity events in children 6 to <16 weeks of age, cold-adapted influenza vaccine, trivalent, was generally well tolerated in infants 6 to <24 weeks of age. These findings support further evaluation of cold-adapted influenza vaccine, trivalent, in infants <6 months of age.

Diabetes Continues to Rise

(HealthDay News) — News from the diabetes front seems to grow more discouraging by the day.

Rates of the disease, fueled by obesity and sedentary lifestyles, have risen unchecked in the United States, with diabetes now affecting about 7 percent of the population. That’s an estimated 20.8 million adults and children, according to the American Diabetes Association.

Federal projections estimate that by 2050, some 48 million Americans will have type 2 diabetes. And the disease will bring with it complications such as blindness, hearing loss, kidney disease, nervous system disorders and amputations of extremities.

“Studies have suggested that for the first time in history, the generation of people born in 2000 is probably going to have shorter life expectancy than their parents,” said Dr. Sue Kirkman, vice president of clinical affairs for the American Diabetes Association. “That’s attributable to obesity, diabetes and heart disease. Is that what we want for our children?”

What’s worse, one of the most promising medicines for treating type 2 diabetes — Avandia — now appears to increase a person’s risk of heart attack and heart failure, according to recent studies.

Still, medical experts say the fight against diabetes can be won — if everyone decides to do what’s best for themselves and their families.

That fight will get its yearly boost on Tuesday when the American Diabetes Association will “sound the alert” about diabetes on the 20th annual American Diabetes Alert Day. It’s a one-day “call to action” to encourage those at risk for developing type 2 diabetes or those with loved ones at risk to take the Diabetes Risk Test and, if they score high, to schedule an appointment to see their health-care provider. The Diabetes Risk Test is available in English and Spanish by calling the association at 1-800-DIABETES (1-800-342-2383) or online at www.diabetes.org/alert.

But the finding on Avandia calls into question the safety of the entire class of drugs known as thiazolidinediones. For now, Avandia — and other thiazolidinediones such as Actos — remains on the market. But last year, the U.S. Food and Drug Administration mandated stricter labeling, including “black box” warnings, for the medications.

Medical experts recommend that each person discuss with their physician the risks and rewards of using Avandia.

“Every patient is different,” said Kirkman. “Every patient has different risk factors. Every patient has reasons why one medicine might be better for them than another.”

But medicines are only part of the solution. A better response would be drastic changes to American lifestyles, starting with improved diets and more exercise, to avoid type 2 diabetes in the first place.

“The statistics are pretty gloomy, but we also know people who are at risk for diabetes can do a lot to prevent it from coming on,” Kirkman said. “There’s a lot people can do to try and control their fate.”

Diabetes comes in two types.

The most common form, type 2, or what used to be called adult-onset diabetes, occurs when either the body does not produce enough of the hormone insulin or the cells ignore the insulin. The body needs insulin to transport sugar in the blood to cells for energy. Being overweight, an unhealthy diet, and lack of exercise are common contributors to this form of the disease.

Type 1 diabetes, usually diagnosed in children and young adults, occurs when the body isn’t capable of producing insulin.

Researchers reviewing data from the National Health Interview Survey found that from 1990 to 2005, cases of diabetes increased 4.6 percent each year. They rose from 26.4 cases per 1,000 people to 54.5 per 1,000 people in the most recent year available.

The diabetes epidemic has grave implications for America, said Martha Funnell, a clinical nurse specialist for the University of Michigan and a past president of the American Diabetes Association. Health care costs are expected to soar as more people with diabetes complications fill doctors’ offices and emergency rooms.

Even the U.S. economy will be affected as potentially healthy people find themselves unable to work. “You’re losing folks in the prime of their years, and that has an impact on society and our economy,” Funnell said.

Fortunately, there are steps that can be taken, both large and small, to help fight diabetes.

On the large-scale side, Kirkman said, governments should spend more money on physical education in schools and on public transportation, instead of new road construction.

“We know people who take public transportation are more physically active,” she said. “Do we choose to encourage that?”

On a more personal level, people can make healthy lifestyle choices and help pass those choices along to their children, Funnell said.

But is anyone listening and willing to try?

“The messages are those same old ‘eat healthy and exercise,’ and we hear those to the point where we think, ‘Yeah, yeah, yeah, everybody knows we need to do these things,’ ” Funnell said.

However, even small measures — standing more often during the day or walking during a lunch break or eating an apple instead of ice cream — can help make a difference.

“Maybe it would seem to outsiders as a small step, but it’s just taking that one step and the next step and the next,” Funnell said. “Like global warming, it’s saying, ‘What can I do for myself and my family this week, this month, this year, that will make a difference?’ “

Those Most At Risk, Referred Less for Colonoscopies

This is not surprising based on the research that demonstrated that if you do not have insurance, you are not tested for certain serious conditions until it may be too late. I posted the article earlier, click here to read it.

(HealthDay News) — Even when there is a family history of colon cancer, blacks are much less likely to get colonoscopies than their white counterparts are, a new study finds.

While blacks who have an increased chance of developing colon cancer continue to lag behind their white counterparts in colonoscopy rates, the lack of a doctor referral stood out as the primary reason why high-risk patients of either race had not been screened.

For people who have close relatives that have been diagnosed with colon cancer, the recommended screening is a colonoscopy every five years after the age of 40.

“People with a family history of colon cancer have a two to four times increased risk of developing the disease compared with people who don’t have such a history,” explained lead researcher Dr. Harvey J. Murff, an assistant professor of medicine at Vanderbilt University in Nashville, Tenn.

“When you look at people who have more than one close relative diagnosed with colon cancer, African-Americans were about half as likely to have reported undergoing the appropriately recommended screening as compared to whites,” Murff said.

The reasons for this disparity aren’t clear, Murff said. It could be that doctors don’t perceive blacks as having an increased risk for colon cancer, he speculated. It may also be that doctors are remiss in collecting a complete family medical history, he said.

“If providers aren’t aware of family history, they may be less likely to recommend the test,” Murff said. “There is a problem collecting family history and using it to risk-assess patients.”

Other conditions that limit access to care, such as not having health insurance or a usual care provider, may also play a role, Murff said.

The report was published in the March 24 issue of the Archives of Internal Medicine.

In the study, Murff’s group collected data on 41,830 people aged 40 to 79. Among these, 32,265 were black and 9,565 were white. The researchers specifically looked at how these patients were screened for colon cancer.

There were 538 blacks who reported having close relatives diagnosed with colon cancer, compared with 255 whites. Among blacks, 27.3 percent reported having a colonoscopy within the past five years, compared with 43.1 percent of whites.

The main reason for not having a colonoscopy among both blacks and whites was that their doctor had not recommended one. Among blacks, 59.3 percent said their doctor had not recommended a colonoscopy, compared with 51 percent of whites.

Doctors need to be sure that they get a complete family medical history, Murff said. “In addition, it is important for patients to know what your family history is, and if you have questions related to your family history or if you are concerned that it might impact your risk of disease, it is important to talk to your physician about it,” he said.

Tips: Make sure you know possible signs, click here for more information.

Taking a Page From Homeopathy: Pharmacogenomics and Its Role In Drug Safety

Interesting quote in this FDA newsletter by Sir William Osler. Allopathic medicine continues to attempt to include [selected] homeopathic principles [treating the individual, the minimum dose, etc.] in its applications. However since the premise is incorrect (e.g. what is disease, who and what is man, the role of soil and diet in health, etc.) it won’t work.

FDA Drug Safety Newsletter
Volume 1, Number 2

Winter 2008

Feature Article: Pharmacogenomics and Its Role In Drug Safety

“Variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions which we know as disease…”
- Sir William Osler (1849-1919)

Pharmacogenomics is the science of determining how genetic variability influences physiological responses to drugs, from absorption and metabolism to pharmacologic action and therapeutic effect.1 With increasing knowledge of the molecular basis for a drug’s action has come the recognition of the importance of an individual’s genetic makeup in influencing how he or she may respond to a drug.


This understanding of the genetic variations in drug response opens the door to “personalized medicine” by (1) identifying patients who are more prone to experience adverse events from a drug and (2) identifying patients who are more likely to benefit from a particular therapy. This information has the potential to guide the selection of a drug for a particular patient and to tailor the drug dose to achieve the optimal therapeutic effect. In addition, knowledge of the genetic makeup of infectious agents is being used to guide treatment. For example, the identification of the specific drug resistance mutations in a patient’s human immunodeficiency virus (HIV) is used to select the therapy most suitable or best “targeted” for that patient. In these ways, pharmacogenomics has the potential to assist physicians in adapting drug treatments to the characteristics of individual patients, ultimately leading to safer and more effective prescribing and dosing.

Pharmacogenomics determines how genetic variability influences response to a drug.Potential applications in the clinic:

  • Tailor dosing to decrease risk of adverse events.
  • Identify patients for targeted therapy.
  • Detect viral drug resistance.

View the table2 of drugs with pharmacogenomics information provided in product labeling.

Improving Dosing and Decreasing Adverse Events

Genetic variants in drug metabolizing enzymes can have a significant effect on the way a person responds to a drug. They can speed up or slow down enzymatic activity, or even inactivate an enzyme. In some patients, known as rapid metabolizers, drugs are metabolized too quickly. As a result, the average dose of the drug may be broken down too quickly to be effective, and a higher dose may be needed. Conversely, where the metabolite of the drug is active, as in the case of codeine (see below), rapid metabolism may lead to excessive accumulation of the active metabolite, which may result in toxic levels. In slow metabolizers, a drug administered at the recommended dose can accumulate due to such slow metabolism, potentially reaching toxic levels in the patient’s system and leading to adverse reactions. Such patients may require a smaller dose. In conjunction with other factors, pharmacogenomics offers the potential to enable doctors to identify the patients who are rapid or slow metabolizers of certain drugs and to adjust dosing accordingly to achieve both effective and safe treatment.

Rapid metabolizers may break down a drug too quickly and require higher doses.Slow metabolizers may build up toxic levels of the drug and require smaller doses.

Clinical Applications of Pharmacogenomics

Warfarin (Coumadin and generics), an anticoagulant, is a recent example of the clinical use of pharmacogenomics to improve dosing. Warfarin has a narrow therapeutic window and a wide range of inter-individual variability in response, requiring careful clinical dose adjustment for each patient. Genetic variants in the warfarin target, the vitamin K epoxide reductase (VKORC1), as well as the warfarin metabolizing enzyme, cytochrome P450 2C9 (CYP2C9), influence the variation in patient response. Patients with certain variants of these genes eliminate warfarin more slowly and typically require lower warfarin doses. In those individuals, a traditional warfarin dose would more likely lead to an elevated International Normalized Ratio (INR), a longer time to achieve a stable warfarin dose, and a higher risk of serious bleeding events during the induction or dose-titration period of warfarin therapy.3 (FDA News)

Another recent example involves ultrarapid metabolizers of codeine, who have multiple copies of the gene for cytochrome P450 2D6 (CYP2D6), the enzyme that converts codeine into morphine, its active metabolite. Nursing mothers who are taking codeine and are ultra-rapid metabolizers could have high levels of morphine in their breast milk, increasing the risk of morphine overdose in their nursing infant.4 Although most nursing mothers can take codeine safely after childbirth, healthcare practitioners should prescribe the lowest dose for the shortest period of time to relieve pain and nursing infants should be carefully monitored when breastfeeding women receive this drug. (FDA Information to Healthcare Professionals)

Pharmacogenomic studies have recently identified a genetic marker in patients, the human leukocyte antigen (HLA) allele HLA-B*1502, which is associated with dangerous, sometimes fatal, skin reactions (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)) following treatment with the antiepileptic drug carbamazepine (Carbatrol PDF document, Equetro PDF document, Tegretol PDF document, and generics).5 Since the HLA-B*1502 allele is found almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians, healthcare practitioners should screen patients with ancestry in at-risk populations for the HLA-B*1502 allele prior to initiating treatment with carbamazepine.6,7,8,9 Patients who test positive for HLA-B*1502 should not be treated with carbamazepine unless the expected benefit clearly outweighs the increased risk of SJS/TEN. In weighing these risks and benefits, it is important to recognize that other antiepileptic drugs are associated with these serious skin reactions as well. (FDA Information for Healthcare Professionals Sheet)

Tests to identify the three genetic polymorphisms for warfarin, codeine, and carbamazepine described above are commercially available.

A table2 describing the valid genomic biomarkers that are currently part of FDA-approved drug labels can be found at http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm The table provides a list of these markers, links to pharmacogenomic data that support their validity, and recommendations for the clinical use of some of these biomarkers.

Pharmacogenomics Leads To More Effective Targeted Therapies

The incorporation of genomics in the preclinical and clinical research of anticancer drugs has resulted in significant progress in the development of new drugs. Discovering targeted therapies that are specifically directed at tumor cells with particular protein characteristics that differ from those of normal cells has been a primary focus of innovation in cancer treatment. Targeting drugs specifically to tumor cells can decrease the toxic effects of anticancer drugs on normal cells. For some targeted therapies, diagnostic genetic tests that can help identify the tumors that are likely to respond to those particular treatments have been co-developed with the drug. Examples of these drugs and their targets include:

  • Imatinib (Gleevec PDF document) for bcr-abl tyrosine kinase in several tumor types
  • Cetuximab (Erbitux PDF document) for epidermal growth factor receptor (EGFR) in head and neck cancer and colorectal cancer
  • Trastuzumab (Herceptin PDF document) for variants in the Her2 receptor in breast cancer
Targeted therapies are directed at tumor cells with particular protein characteristics that differ from normal cells.

Pharmacogenomics Can Detect Drug Resistance in Viruses

The HIV genomes are constantly and rapidly evolving. Changes in targeted viral proteins may cause the HIV virus to become resistant to anti-viral drugs or vaccines. HIV patients often have to try different drug combinations when the virus becomes resistant to drugs they are taking. An FDA-approved kit, the TRUGENE HIV-1 Genotyping Kit PDF document, is now commercially available to detect several drug-resistance gene variants in the protease and reverse-transcriptase regions of the HIV virus. These two regions are targets of anti-retroviral treatments. If drug resistance is found to be present, the physician can alter the treatment regimen accordingly.

FDA’s Role in Pharmacogenomics and Personalized Medicine

Pharmacogenomics holds the promise to individualize our healthcare and to improve drug safety and effectiveness for the population as a whole. FDA is in a unique position to promote pharmacogenomics and personalized medicine. It encourages the incorporation of pharmacogenomics in the drug development process (Genomics at FDA). In 2004, FDA launched the Critical Path Initiative, a national effort to stimulate and facilitate the modernization of the sciences through which regulated products are developed, evaluated, and manufactured. The Critical Path Initiative is aimed at facilitating development of innovative tools, such as predictive genetic tests, valid biomarkers, assays, and information technology, to enable the efficient development and evaluation of safer and more effective drugs and promote the safe use of FDA-regulated products.

As part of the Critical Path Initiative, FDA is working to develop guidance for the pharmaceutical industry on co-development of drugs and diagnostic tests. FDA is also collaborating with the National Institutes of Health (NIH) and other research institutions in applied research efforts to study the genetic basis of drug-related toxicities. These research networks are working to improve the safety profiles of drugs in preclinical and clinical development as well as those, like warfarin and carbamazepine, that are already in the marketplace. Much work remains in understanding the role that genetics plays in achieving the goal of tailoring therapeutics to the individual patient.

References

  1. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov. 2004;3(9):763-9.
  2. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels, available at : http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm, Accessed on January 23, 2008
  3. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2007;25(1):45-51.
  4. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2007;368(9568):704.
  5. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
  6. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7(6):813-818.
  7. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16(4):297-306.
  8. Lonjou C, Thomas L, Borot N, et al., RegiSCAR Group. A marker for Stevens-Johnson syndrome …: ethnicity matters. Pharmacogenomics J. 2006;6(4):265-268.
  9. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015-1018.

horizonal rule

Research News – How To Heal Faster

anger.jpg

To heal from wounds and injuries the body has to rally its resources. The immune system gears up for the challenge…then stalls. Instead of healing the bruises, bumps and burns it sputters out, and the healing slows down.

What makes some people heal faster than others? There are a number of factors of course. In exploring the body-mind connection in wound healing, researchers observed that subjects who held on to an angry, irritated state of mind took longer to heal. Interesting right? Keeping cool and calm facilitates healing.

Here is the research…

The influence of anger expression on wound healing.

Gouin JP, Kiecolt-Glaser JK, Malarkey WB, Glaser R.

Department of Psychology, The Ohio State University, USA; Institute for Behavioral Medicine Research, Ohio State University College of Medicine, USA.

Certain patterns of anger expression have been associated with maladaptive alterations in cortisol secretion, immune functioning, and surgical recovery. We hypothesized that outward and inward anger expression and lack of anger control would be associated with delayed wound healing. A sample of 98 community-dwelling participants received standardized blister wounds on their non-dominant forearm. After blistering, the wounds were monitored daily for 8 days to assess speed of repair. Logistic regression was used to distinguish fast and slow healers based on their anger expression pattern. Individuals exhibiting lower levels of anger control were more likely to be categorized as slow healers. The anger control variable predicted wound repair over and above differences in hostility, negative affectivity, social support, and health behaviors. Furthermore, participants with lower levels of anger control exhibited higher cortisol reactivity during the blistering procedure. This enhanced cortisol secretion was in turn related to longer time to heal.These findings suggest that the ability to regulate the expression of one’s anger has a clinically relevant impact on wound healing.

Content Protected Using Blog Protector Plugin By: Make Money.

Optimized by SEO Ultimate